^
Association details:
Biomarker:MSI-H/dMMR
Cancer:Vulvar Cancer
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/26/2021
Excerpt:
Vulvar cancer (Squamous cell carcinoma): Advanced or recurrent/metastatic disease…Biomarker-directed systemic therapy for second-line treatment…Pembrolizumab (second-line therapy for TMB-H, PD-L1-positive, or MSI-high [MSI-H]/MMR deficient [dMMR] tumors)
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Small Intestinal Carcinoma)
New
Title:

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

Excerpt:
Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Excerpt:
...- Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR...
Trial ID: